Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.51 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.46 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13674748 | 1.00 | EPHX1 (0.57) | EPHX1ALDH1A1HPGDCYP19A1TRPA1 | |
| SCHEMBL13476390 | 1.00 | EPHX1 (0.57) | EPHX1ALDH1A1HPGDCYP19A1TRPA1 | |
| SCHEMBL13675571 | 1.00 | EPHX1 (0.57) | EPHX1ALDH1A1HPGDCYP19A1TRPA1 | |
| SCHEMBL6701412 | 1.00 | EPHX1 (0.57) | EPHX1ALDH1A1HPGDCYP19A1TRPA1 | |
| SCHEMBL13674746 | 1.00 | EPHX1 (0.57) | EPHX1ALDH1A1HPGDCYP19A1TRPA1 | |
| SCHEMBL6737565 | 1.00 | EPHX1 (0.57) | EPHX1ALDH1A1HPGDCYP19A1TRPA1 | |
| SCHEMBL13476726 | 1.00 | EPHX1 (0.57) | EPHX1ALDH1A1HPGDCYP19A1TRPA1 | |
| SCHEMBL16387737 | 1.00 | EPHX1 (0.57) | EPHX1ALDH1A1HPGDCYP19A1TRPA1 | |
| SCHEMBL14226245 | 1.00 | EPHX1 (0.57) | EPHX1ALDH1A1HPGDCYP19A1TRPA1 | |
| SCHEMBL15335366 | 1.00 | EPHX1 (0.57) | EPHX1ALDH1A1HPGDCYP19A1TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220213210-A1 | COMBINATION THERAPY OF MULTIPLE SCLEROSIS COMPRISING A CD20 LIGAND | MABION SA (PL) | 2022-07-07 | — | — | US | disclosed |
| US-11026920-B2 | Use of NK-1 receptor antagonist serlopitant in pruritus | VYNE THERAPEUTICS INC. (US) | 2021-06-08 | — | — | US | disclosed |
| US-20200306224-A1 | USE OF NK-1 RECEPTOR ANTAGONIST SERLOPITANT IN PRURITUS | VYNE THERAPEUTICS INC. | 2020-10-01 | — | — | US | disclosed |
| US-10702499-B2 | Use of NK-1 receptor antagonists in pruritus | MENLO THERAPEUTICS INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-10617671-B2 | Use of NK-1 receptor antagonist serlopitant in pruritus | MENLO THERAPEUTICS INC. (US) | 2020-04-14 | — | — | US | disclosed |
| US-20200054604-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS IN PRURITUS | VYNE THERAPEUTICS INC. (F/K/A MENLO THERAPEUTICS INC. AND SUCCESSOR-IN-INTEREST TO VYNE PHARMACEUTICALS LTD., F/K/A FOAMIX PHARMACEUTICALS LTD.) | 2020-02-20 | — | — | US | disclosed |
| US-20200054603-A1 | USE OF NK-1 RECEPTOR ANTAGONIST SERLOPITANT IN PRURITUS | VYNE THERAPEUTICS INC. (F/K/A MENLO THERAPEUTICS INC. AND SUCCESSOR-IN-INTEREST TO VYNE PHARMACEUTICALS LTD., F/K/A FOAMIX PHARMACEUTICALS LTD.) | 2020-02-20 | — | — | US | disclosed |
| US-10463901-B2 | Use of metal-accumulating plants for the preparation of catalysts that can be used in chemical reactions | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2019-11-05 | — | — | US | disclosed |
| US-10278953-B2 | Use of NK-1 receptor antagonist serlopitant in pruritus | MENLO THERAPEUTICS INC. (US) | 2019-05-07 | — | — | US | disclosed |
| US-10278952-B2 | Use of NK-1 receptor antagonists in pruritus | MENLO THERAPEUTICS INC. (US) | 2019-05-07 | — | — | US | disclosed |
| US-20040034223-A1 | Amphiphilic molecular modules and constructs based thereon | COVALENT PARTNERS, LLC. | 2004-02-19 | — | — | US | disclosed |
| US-20030199688-A1 | Macrocyclic module compositions | COVALENT PARTNERS, LLC | 2003-10-23 | — | — | US | disclosed |
| WO-1996022960-A1 | PROCESS FOR PRODUCING 2,2-DIHYDROXYACETIC ACID MENTHYL ESTER | LONZA AG (CH) | 1996-08-01 | — | — | WO | disclosed |
| EP-0458363-B1 | Fluorinated bis(hydroxymethyl) cyclobutyl purines and pyrimidines | SQUIBB & SONS INC (US) | 1996-02-07 | — | — | EP | disclosed |
| EP-0458643-B1 | Process for preparing an optically active cyclobutanone, an intermediate in the synthesis of an optically active cyclobutane nucleoside | SQUIBB & SONS INC (US) | 1995-11-29 | — | — | EP | disclosed |
| US-5344962-A | Intermediates in the synthesis of an optically active cyclobutane nucleoside | E. R. SQUIBB & SONS, INC. (US) | 1994-09-06 | — | — | US | disclosed |
| US-5233076-A | Process for preparing an optically active cyclobutanone, an intermediate in the synthesis of an optically active cyclobutane nucleoside | E. R. SQUIBB & SONS, INC. (US) | 1993-08-03 | — | — | US | disclosed |
| WO-1991018969-A1 | FLUORINATED BIS(HYDROXYMETHYL)CYCLOBUTYL PURINES AND PYRIMIDINES | E.R. SQUIBB & SONS, INC. (US) | 1991-12-12 | — | — | WO | disclosed |
| EP-0458363-A1 | Fluorinated bis(hydroxymethyl) cyclobutyl purines and pyrimidines | E.R. SQUIBB & SONS, INC. (US) | 1991-11-27 | — | — | EP | disclosed |
| EP-0458643-A2 | Process for preparing an optically active cyclobutanone, an intermediate in the synthesis of an optically active cyclobutane nucleoside | E.R. SQUIBB & SONS, INC. (US) | 1991-11-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199688-A1 | Macrocyclic module compositions | CYCS, IMMT, INTS9 | EPHX1 3812/4885ALDH1A1 4880/4885HPGD 1804/4885 |
| US-10702499-B2 | Use of NK-1 receptor antagonists in pruritus | TACR1, CYSLTR1, HRH3 | EPHX1 588/4885ALDH1A1 2009/4885HPGD 1641/4885 |
| US-10278952-B2 | Use of NK-1 receptor antagonists in pruritus | TACR1, CYSLTR1, HRH3 | EPHX1 588/4885ALDH1A1 2009/4885HPGD 1641/4885 |
| US-10617671-B2 | Use of NK-1 receptor antagonist serlopitant in pruritus | TACR1, CYSLTR1, NPSR1 | EPHX1 672/4885ALDH1A1 2186/4885HPGD 1492/4885 |
| US-20200054603-A1 | USE OF NK-1 RECEPTOR ANTAGONIST SERLOPITANT IN PRURITUS | TACR1, CYSLTR1, NPSR1 | EPHX1 672/4885ALDH1A1 2186/4885HPGD 1492/4885 |
| US-20200054604-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS IN PRURITUS | TACR1, CYSLTR1, HRH3 | EPHX1 588/4885ALDH1A1 2009/4885HPGD 1641/4885 |
| US-20040034223-A1 | Amphiphilic molecular modules and constructs based thereon | ANXA6, THEM6, ANXA5 | EPHX1 1648/4885ALDH1A1 4330/4885HPGD 4706/4885 |
| US-20200306224-A1 | USE OF NK-1 RECEPTOR ANTAGONIST SERLOPITANT IN PRURITUS | TACR1, CYSLTR1, NPSR1 | EPHX1 672/4885ALDH1A1 2186/4885HPGD 1492/4885 |
| US-20220213210-A1 | COMBINATION THERAPY OF MULTIPLE SCLEROSIS COMPRISING A CD20 LIGAND | CD209, MSR1, SIGLEC7 | EPHX1 1975/4885ALDH1A1 2669/4885HPGD 4162/4885 |
| US-11026920-B2 | Use of NK-1 receptor antagonist serlopitant in pruritus | TACR1, CYSLTR1, NPSR1 | EPHX1 672/4885ALDH1A1 2186/4885HPGD 1492/4885 |
| US-10278953-B2 | Use of NK-1 receptor antagonist serlopitant in pruritus | TACR1, CYSLTR1, NPSR1 | EPHX1 672/4885ALDH1A1 2186/4885HPGD 1492/4885 |
| US-10463901-B2 | Use of metal-accumulating plants for the preparation of catalysts that can be used in chemical reactions | PICALM, MAX, MGAM | EPHX1 4374/4885ALDH1A1 4394/4885HPGD 1904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.